Recurrent Melanoma Completed Phase 2 Trials for DB00112 (Bevacizumab)

IndicationStatusPhase
DBCOND0028662 (Recurrent Melanoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00387751Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant MelanomaTreatment
NCT00026221Bevacizumab With or Without Interferon Alfa in Treating Patients With Metastatic Malignant MelanomaTreatment
NCT00255762Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By SurgeryTreatment
NCT00397982Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant MelanomaTreatment